Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia

Supportive Care in Cancer

Volumn 8, Issue 5, 2000, Pages 398-404

  Body, J J ^a,b   Louviaux, I ^a   Dumon, J C ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bisphosphonate; Bone; Breast cancer; Hypercalcemia; Osteoclast

Indexed keywords

CALCIUM; HYDROXYPROLINE; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYDROXYPROLINE URINE LEVEL; HYPERCALCEMIA; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; NEOPLASMS; OSTEOCLASTS; RECURRENCE; TREATMENT OUTCOME;

EID: 0033842560     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050008     Document Type: Article

References (22)

1. Cancer-associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients
2. Treatment of tumour-induced hypercalcemia with the bisphosphonate pamidronate. Dose-response relationship and influence of tumour type
3. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60- and 90-mg dosages
4. Randomised double-blind comparison of pamidronate or clodronate for hypercalcemia of malignancy: Effects on bone metabolism markers
5. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD)
6. Response to retreatment of malignant hypercalcaemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone
7. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphonate (APD)
8. Current use of bisphosphonates in oncology
9. Circulating PTHrP concentrations in tumor-induced hypercalcemia: Influence on the response to bisphosphonate and changes after therapy
10. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate
11. Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer
12. Modified immunoradiometric assay of parathyroid hormone-related protein: Clinical application in the differential diagnosis of hypercalcemia
13. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone
14. Randomized phase II trial comparing different doses of bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
15. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy
16. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia
17. Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD)
18. Parathyroid hormone related protein and response to pamidronate in tumor-induced hypercalcemia
19. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans
20. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy
21. Humoral hypercalcemia of malignancy: Some enigmas on the clinical features